Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen has secured approval from China’s National Medical Products Administration for a new indication of its flagship antibody-drug conjugate Disitamab Vedotin, in combination with immunotherapy drug Toripalimab, as a first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma, marking the drug’s fifth approved indication in China. The approval, supported by a large Phase III trial showing significantly improved survival and response rates over platinum-based chemotherapy across the full spectrum of HER2 expression with a favorable safety profile, strengthens RemeGen’s position in the competitive oncology market and expands treatment options for patients with a high-burden, historically hard-to-treat cancer type in China.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$124.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a China-based biopharmaceutical company specializing in the research, development and commercialization of innovative antibody-drug conjugates and other targeted oncology therapies. Its lead product Disitamab Vedotin is China’s first domestically developed HER2-targeting ADC, aimed at treating multiple solid tumors including gastric, urothelial and breast cancers, with a focus on high-incidence, high-unmet-need indications in China and globally.
Average Trading Volume: 4,409,670
Technical Sentiment Signal: Buy
Current Market Cap: HK$78.08B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.